Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-907

10 evidence topics · 3 sources

Objective
Location and study date
Trial dates and status in the EU register
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using Obefazimod pharmacokinetics in renal impairment as the study endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results

No evidence found.

Study limitations
Summary

ABX464-907 has only an EU register record. The register gives the title, the dates (9 September 2024 to 14 October 2025), one site in Germany, and 48 planned participants, who include patients and healthy volunteers aged 18 years or older. The Form 20-F does not name this trial among the completed Phase 1 trials. The categories of renal impairment, the dose, the number per group, the inclusion of participants on dialysis, and the endpoints are not public, and the summary of results is deferred until 14 April 2028. No exposure or safety result is available to inform dosing in renal impairment.